Low Dose Single Weekly Injections of Growth Hormone: Response during First Year of Therapy of Hypopituitarism

PEDIATRICS ◽  
1980 ◽  
Vol 66 (2) ◽  
pp. 272-276
Author(s):  
Arlan L. Rosenbloom ◽  
William J. Riley ◽  
Janet H. Silverstein ◽  
Adolfo D. Garnica ◽  
Michael L. Netzloff ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Standard Dose ◽  
Collaborative Study ◽  
Human Growth ◽  
Hormone Deficiency ◽  
First Year ◽  
Growth Responses ◽  
The Us ◽  
Study Experience ◽  
British Experience

Initial year growth responses to single weekly injections of 2.5 units human growth hormone (hGH) in 29 patients with hypopituitarism (130 units/yr/patient) were compared to responses in a series using smaller doses in conjunction with androgen (48 to 112 units/yr); the US collaborative study experience with the standard dose (2 units 3 times/wk = 312 units/yr), and with two size-adjusted doses (0.06 units/kg 3 times/wk = 212 ± 94 SD units/yr, 0.03 units/kg 3 times/wk = 116 ± 33 units/yr); and to the British experience with much larger doses (1,040 units/yr). During the first year of hGH treatment our patients grew an average 13% faster than the androgen-supplemented and collaborative study-0.03 units/kg/dose groups. They had a similar pace to the collaborative study-312 units/yr and 0.06 units/kg/dose patients, but grew 15% more slowly than did the British patients. Growth response correlated positively with age and negatively with hGH dose per kilogram of body weight. Of 17 patients with isolated growth hormone deficiency ten developed hypothyroidism with hGH therapy, leading to a policy of routine adjunctive thyroxine replacement.

Collaborative Study of the Effects of Human Growth Hormone in Growth Hormone Deficiency. I. First Year of Therapy

1972 ◽  
Vol 35 (4) ◽  
pp. 483-496 ◽  
Author(s):  
THOMAS ACETO ◽  
S. DOUGLAS FRASIER ◽  
ALVIN B. HAYLES ◽  
HEINO F. L. MEYER-BAHLBURG ◽  
MARY L. PARKER ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Human Growth Hormone ◽  
Collaborative Study ◽  
Human Growth ◽  
Hormone Deficiency ◽  
First Year

scholarly journals Validating genetic markers of response to recombinant human growth hormone in children with growth hormone deficiency and Turner syndrome: the PREDICT validation study

2016 ◽  
Vol 175 (6) ◽  
pp. 633-643 ◽  
Author(s):  
Adam Stevens ◽  
Philip Murray ◽  
Jerome Wojcik ◽  
John Raelson ◽  
Ekaterina Koledova ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Random Forest ◽  
Growth Hormone Deficiency ◽  
Genetic Markers ◽  
Validation Study ◽  
Growth Response ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Hormone Deficiency ◽  
First Year

Objective Single-nucleotide polymorphisms (SNPs) associated with the response to recombinant human growth hormone (r-hGH) have previously been identified in growth hormone deficiency (GHD) and Turner syndrome (TS) children in the PREDICT long-term follow-up (LTFU) study (Nbib699855). Here, we describe the PREDICT validation (VAL) study (Nbib1419249), which aimed to confirm these genetic associations. Design and methods Children with GHD (n = 293) or TS (n = 132) were recruited retrospectively from 29 sites in nine countries. All children had completed 1 year of r-hGH therapy. 48 SNPs previously identified as associated with first year growth response to r-hGH were genotyped. Regression analysis was used to assess the association between genotype and growth response using clinical/auxological variables as covariates. Further analysis was undertaken using random forest classification. Results The children were younger, and the growth response was higher in VAL study. Direct genotype analysis did not replicate what was found in the LTFU study. However, using exploratory regression models with covariates, a consistent relationship with growth response in both VAL and LTFU was shown for four genes – SOS1 and INPPL1 in GHD and ESR1 and PTPN1 in TS. The random forest analysis demonstrated that only clinical covariates were important in the prediction of growth response in mild GHD (>4 to <10 μg/L on GH stimulation test), however, in severe GHD (≤4 μg/L) several SNPs contributed (in IGF2, GRB10, FOS, IGFBP3 and GHRHR). Conclusions The PREDICT validation study supports, in an independent cohort, the association of four of 48 genetic markers with growth response to r-hGH treatment in both pre-pubertal GHD and TS children after controlling for clinical/auxological covariates. However, the contribution of these SNPs in a prediction model of first-year response is not sufficient for routine clinical use.

Isolated human growth hormone deficiency due to the hGH-I gene deletion with (type IA) and without (the Israeli-type) hGH antibody formation during hGH therapy

1990 ◽  
Vol 122 (2) ◽  
pp. 267-271 ◽  
Author(s):  
Yoshikazu Nishi ◽  
Hiroyuki Masuda ◽  
Shinichiro Nishimura ◽  
Mikio Kihara ◽  
Seizo Suwa ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Human Growth Hormone ◽  
Antibody Formation ◽  
Gene Deletion ◽  
Human Growth ◽  
Japanese Patients ◽  
Hormone Deficiency ◽  
Growth Responses ◽  
I Gene

Abstract Three Japanese patients with isolated growth hormone deficiency from two different families were shown to be homozygous for deletion of the structural gene for human growth hormone (hGH-I gene). These three patients had the same restriction fragment length polymorphism haplotypes. In patient No. 1, the growth rate initially responded well to pituitary human growth hormone, but growth rapidly ceased concomitantly with the development of high levels of anti-hGH antibodies. He again responded well to recombinant methionyl hGH and recombinant hGH without the methionine residue, even though having high hGH antibodies. Two siblings (Patients No. 2 and 3) showed a rather good response to pituitary hGH treatment without hGH antibodies ever being detected (the Israeli-type). hGH-I gene deletions may not necessarily result in hGH antibody formation. Heterogeneity has been observed in isolated hGH deficiency due to hGH-I gene deletion. hGH-I gene analysis should not be limited to patients with hGH antibody formation and subnormal growth responses to hGH therapy.

Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children

1983 ◽  
Vol 104 (2) ◽  
pp. 148-152 ◽  
Author(s):  
K. W. Kastrup ◽  
J. Sandahl Christiansen ◽  
J. Koch Andersen ◽  
H. Ørskov
Keyword(s):  
Growth Hormone ◽  
Growth Rate ◽  
Growth Response ◽  
Pubertal Development ◽  
Human Growth ◽  
Bone Age ◽  
Hormone Deficiency ◽  
First Year ◽  
Weekly Dose ◽  
Second Year

Abstract. The effect of more frequent (daily) injections of human growth hormone (hGH) on growth rate was studied in 16 growth hormone deficient children (12 boys, 4 girls) during 2 years. All had previously been treated with im injection of hGH 2–3 times weekly and in the majority of the patients a waning growth response was observed. For a total weekly dose of 12 IU hGH a daily dose of 2 IU was injected sc at night before sleep. This dosage has been shown by us to imitate the average nocturnal hGH profile in plasma. Growth response on the im treatment was 5.2 ± 1.2 cm/year (sd) in boys and 5.4 ± 0.9 cm/year in girls. A significant increase was seen during the first year of sc treatment to 7.9 ± 2.7 cm in boys and 6.3 ± 2cm in girls. During the second year the growth response was still significantly increased in boys (7.2 ± 1.9 cm). Bone age was more advanced and the period of previous im treatment was longer in girls (6.7 vs 3.6 years) which may be the main cause of the waning second year response (4.7 ±1.3 cm/year). Pubertal development occurred in 9 children during treatment. However, the highest growth rates were not found in these children. Absence of antibodies against hGH and local reactions at the injection site is evidence of the safety of the treatment, which was very well accepted by the children. Daily sc injections thus represent an effective alternative to conventional im injections ensuring high acceptance in children with growth hormone deficiency.

Sign in / Sign up

Export Citation Format

Share Document